article
Driving diversity and leadership in the biotech industry
Judy Ashworth, CMO of Novadip Biosciences, shares her journey in advancing treatments for rare paediatric conditions and championing diversity in STEM.
List view / Grid view
Clinical Trials
article
Next-gen ADCs: Tubulis sets new standard in cancer treatment
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
article
AI-powered imaging for faster lung disease treatment
Deep learning is transforming lung disease treatment by enabling earlier diagnosis, precise monitoring and more efficient clinical trials. This article explores how AI-driven imaging is accelerating drug development and improving patient outcomes.
article
LB-102: Redefining schizophrenia treatment in drug discovery
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
article
Advanced drug development for neurodegenerative diseases with α-synuclein
Discover how α-synuclein tests are transforming the diagnosis and treatment of neurodegenerative diseases, offering hope for earlier detection, better-targeted therapies and faster drug development.
article
Early evidence and emerging trends: How AI is shaping drug discovery and clinical development
Drug development is plagued by high costs, long timelines and low success rates, but what if AI could change that? Read on to discover real-world examples and explore the transformative potential of AI in drug development.
news
Study aims to stop Alzheimer’s with stem cell infusions
Researchers at UTHealth Houston have initiated a new stem cell therapy trial aimed at reducing neuroinflammation to prevent Alzheimer's disease before symptoms emerge, an approach that could revolutionise treatment strategies, offering new hope for at-risk individuals.
article
The rising impact of biomarkers in early clinical development
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
news
New melanoma therapy prevents brain metastasis in preclinical studies
A government-funded research team has identified focal adhesion kinase (FAK) as a key driver of melanoma metastasis to the brain. This discovery could revolutionise treatment by not only addressing the condition but also preventing its spread to the brain.
article
Gene silencing: a step forward for rare disease therapy
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
news
Novel radioactive drug targets aggressive metastatic melanoma
Scientists in Japan have developed a new radioactive drug that emits alpha particles, showing promise for targeting metastatic melanoma - an aggressive skin cancer resistant to many conventional treatments.
article
Abelacimab: the next frontier in safer anticoagulation therapy
Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.
article
Navigating the AI revolution: a roadmap for pharma’s future
AI-driven drug development, powered by advanced models and expanding data access, is becoming a reality. Learn why navigating regulatory hurdles and mastering biology’s inherent complexities are crucial to fully unlocking its potential.
news
AI-designed CDK12/13 inhibitors target resistant cancers
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
news
Leukaemia cells hit hard by innovative dual-drug approach
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
